Pharmaceuticals · NYSE: NVO
Novo Nordisk earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 2 Feb 2027
Latest: Q3 2026
Wegovy pill, now launched in eight countries, generated DKK 5,394 million in the quarter as Novo prepares a US CagriSema launch in early 2027.
The oral obesity pill was the main change this quarter. Wegovy pill holds around 80% of US new-to-brand prescriptions and is now launched in eight countries. Ozempic pill has replaced Rybelsus in the US, and Medicare's Bridge programme opened obesity coverage from 1 July. Novo says it is treating 5.6 million people with obesity. Both US and International operations returned to growth, led by obesity.
Quarters
KPI history
20-F filings
- 4 Feb 202620-F for the period ended 31 Dec 2025SEC ↗
- 5 Feb 202520-F for the period ended 31 Dec 2024SEC ↗
- 31 Jan 202420-F for the period ended 31 Dec 2023SEC ↗
- 1 Feb 202320-F for the period ended 31 Dec 2022SEC ↗
- 2 Feb 202220-F for the period ended 31 Dec 2021SEC ↗
- 3 Feb 202120-F for the period ended 31 Dec 2020SEC ↗
- 5 Feb 202020-F for the period ended 31 Dec 2019SEC ↗
- 4 Feb 201920-F for the period ended 31 Dec 2018SEC ↗